May 22, 2024 1:30pm EDT Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 19, 2024 8:53pm EDT Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 17, 2024 4:10pm EDT Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 09, 2024 7:45am EDT Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 02, 2024 9:15am EDT Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
Mar 26, 2024 9:15am EDT Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
Feb 29, 2024 9:15am EST Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
Feb 28, 2024 9:15am EST Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
Jan 22, 2024 9:00am EST Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
Jan 02, 2024 7:05am EST Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
